Safety and immunogenicity of a live recombinant canarypox virus expressing HIV type 1 gp120 MN tm/gag/protease LAI (ALVAC-HIV, vCP205) followed by a p24E-V3 MN synthetic peptide (CLTB-36) administered in healthy volunteers at low risk for HIV infection

AIDS Research and Human Retroviruses

Volumn 15, Issue 7, 1999, Pages 633-645

  Salmon Céron, Dominique ^a,l   Excler, Jean Louis ^b,c   Finkielsztejn, Laurent ^a   Autran, Brigitte ^d   Gluckman, Jean Claude ^d   Sicard, Didier ^a   Matthews, Thomas J ^e   Meignier, Bernard ^b   Valentin, Christian ^b   El Habib, Raphaëlle ^b   Blondeau, Christine ^b   Raux, Maurice ^b   Moog, Christiane ^f   Tartaglia, James ^g   Chong, Pele ^b   Klein, Michel ^b   Milcamps, Bruno ^b   Heshmati, Farad ^a   Plotkin, Stanley ^b   Girard, Marc ^h   Bolognesi, Dani P ^e   Gallo, Robert C ⁱ   Kieny, Marie Paule ^j   Koprowski, Hilary ^k   Kourilsky, Philippe ^h   Lindberg, Alf ^b   more..

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b Pasteur Merieux Connaught   (France)

^c HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e DUKE UNIVERSITY   (United States)

^f INSERM   (France)

^g Virogenetics Inc   (United States)

^h INSTITUT PASTEUR   (France)

ⁱ INSTITUTE OF HUMAN VIROLOGY   (United States)

^j TRANSGENE S A   (France)

^k THOMAS JEFFERSON UNIVERSITY   (United States)

^l Université Paris Descartes   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GAG PROTEIN; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY; PROTEINASE; VIRUS GLYCOPROTEIN;

ANTIBODY RESPONSE; ARTICLE; CELLULAR IMMUNITY; CLINICAL TRIAL; EXPRESSION VECTOR; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; IMMUNOGENICITY; NORMAL HUMAN; PRIORITY JOURNAL;

ADULT; AIDS VACCINES; AMINO ACID SEQUENCE; AVIPOXVIRUS; FEMALE; GENETIC VECTORS; HIV ANTIBODIES; HIV CORE PROTEIN P24; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; IMMUNIZATION SCHEDULE; IMMUNIZATION, SECONDARY; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; PEPTIDES; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, SYNTHETIC;

EID: 2442758677     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922299310935     Document Type: Article

References (43)

1. Haynes BF: HIV vaccines: Where we are and where we are going. Lancet 1996;348:933-937.
2. Montefiori DC, Pantaleo G, Fink LM, Zhou JT, Zhou JY, Bilska M, Miralles GD, and Fauci AS: Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors. J Infect Dis 1996;173:60-67.
3. Pialoux G, Excler JL, Rivière Y, Gonzalez-Canali G, Feuillie V, Coulaud P, Gluckman JC, Matthews TJ, Meignier B, Kieny MP, Gonnet P, Diaz I, Méric C, Paoletti E, Tartaglia J, Salomon H, Plotkin S, the Agis Group, and l'Agence Nationale de Recherche sur le SIDA: A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI). AIDS Res Hum Retroviruses 1995;11:373-381.
4. Clements-Mann ML, Weinhold K, Matthews TJ, Graham B, Gorse GJ, Keefer MC, McElrath MJ, Hsieh RH, Mestecky J, Solla-Pazner S, Mascola J, Schwartz D, Siliciano R, Corey L, Wright P, Belshe R, Dolin R, Jackson S, Xu S, Fast P, Walker MC, Stablein D, Excler JL, Tartaglia J, Duliege AM, Sinangil F, Paoletti E, and the NIAID AIDS Vaccine Evaluation Group: Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1 MN gp120, HIV-1 SF2 recombinant rgp120, or both vaccines in seronegative adults. J Infect Dis 1998;177: 1230-1246.
5. Ada GL and McElrath MJ: HIV type 1 vaccine-induced cytotoxic T-cell responses: Potential role in vaccine efficacy. AIDS Res Hum Retroviruses 1997;13:205-210.
6. Myers G, Korber B, Wain-Hobson S, Jeang KT, Henderson LE, and Pavlakis GN (eds.): Human Retroviruses and AIDS 1996. Los Alamos National Laboratory, Los Alamos, New Mexico, 1996.
7. Lamhamedi-Cherradi S, Culmann-Penciolelli B, Guy B, Kieny MP, Dreyfus F, Saimot AG, Sereni D, Sicard D, Levy JP, and Gomard E: Qualitative and quantitative analysis of human cytotoxic T-lymphocyte responses to HIV-1 proteins. AIDS 1992;6:1249-1258.
8. Goudsmit J, Back NKT, and Nara PL: Genomic diversity and antigenie variation of HIV-1: Links between pathogenesis, epidemiology and vaccine development. FASEB J 1991;5:2427-2436.
9. Venet A and Walker BD: Cytotoxic T-cell epitopes in HIV/SIV infection. AIDS 1993;7(S1):S117-S126.
10. Nixon D, Townsend A, Elvin J, Rizza CR, Gallwey J, and McMichael AJ: HIV-1 Gag-specific cytotoxic T lymphocytes defined with recombinant vaccinia virus and synthetic peptides. Nature (London) 1988;336:484-487.
11. Limbach KJ and Paoletti E: Non-replicating expression vectors: Applications in vaccine development and gene therapy. Epidemiol Infect 1996;116:241-256.
12. Fleury B, Janvier G, Pialoux G, Buseyne F, Robertson MN, Tartaglia J, Paoletti E, Kieny MP, Excler JL, and Rivière Y: Memory cytotoxic T lymphocyte responses in human immunodeficiency virus type 1 (HIV-1)-negative volunteers immunized with a recombinant canarypox expressing gp160 of HIV-1 and boosted with a recombinant gp160. J Infect Dis 1996;174:734-738.
13. Salmon-Céron D, Excler JL, Sicard D, Blanche PH, Finkielstzjen L, Gluckman JC, Autran B, Matthews TJ, Meignier B, Kieny MP, Valentin C, Gonnet P, Diaz I, Salomon H, Pialoux G, Gonzalez-Canali G, Plotkin S, the Agis Group, and l'Agence Nationale de Recherche sur le SIDA: Safety and immunogenicity of a recombinant HIV type 1 glycoprotein 160 boosted by a V3 synthetic peptide in HIV-negative volunteers. AIDS Res Hum Retroviruses 1995;11:1479-1486.
14. Chong P, Sia C, Sydor M, and Klein M: Identification of a potent synthetic HIV-1 immunogen comprising Gag-p24 tandem T-and B-cell epitopes. FEBS Lett 1990;164:231-234.
15. Moog C, Spenlehauer C, Fleury H, Heshmati F, Saragosti S, Letourneur F, Kirn A, and Aubertin AM: Neutralization of primary human immunodeficiency virus type 1 isolates: A study of parameters implicated in neutralization in vitro. AIDS Res Hum Retroviruses 1997;13:19-27.
16. Billaud JN, Yagello M, and Gluckman JC: Primary in vitro sensitization of human T helper lymphocytes by peptides derived from the V3 loop of human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein. Vaccine 1994;12:46-55.
17. Van Eendenburg JP, Yagello M, Girard M, Kieny MP, Lecocq JP, Muchmore E, Fultz P, Riviere Y, Montagnier L, and Gluckman JC: Cell-mediated immune proliferative responses to HIV-1 of chimpanzees vaccinated with different vaccinia recombinant viruses. AIDS Res Hum Retroviruses 1989;5:41-50.
18. Bahraoui E, Yagello M, Billaud JN, Sabatier JM, Guy B, Muchmore E, Girard M, and Gluckman JC: Immunogenicity of the human immunodeficiency virus (HIV) recombinant nef gene product. Mapping of T-cell and B-cell epitopes in immunized chimpanzees. AIDS Res Hum Retroviruses 1990;6:1087-1098.
19. Schaefer ME, Rhodes M, Prince S, Michalek SM, and McGree JR: A plastic intraoral device for the collection of human parotid saliva. J Dent Res 1977;56:728-733.
20. Funkhouser A, Clements ML, Slome S, Clayman B, and Viscidi R: Antibodies to recombinant gp160 in mucosal secretions and sera of persons infected with HIV-1 and seronegative vaccine recipients. AIDS Res Hum Retroviruses 1993;9:627-632.
21. Lu XS, Grangeot-Keros, Blot A, Rannou MT, Delfraissy JF, and Pillot J: Comparison of saliva and serum for HIV antibody testing. In: IXth International Conference on AIDS, Berlin, June 7-11, 1993. [Abstract PO-B40-2457]
22. Plotkin SA, Cadoz M, Meignier B, Méric C, Leroy O, Excler JL, Tartaglia J, Paoletti E, Gonczol E, and Chappuis G: The safety and use of canarypox vectored vaccines. Dev Biol Stand 1995;84: 165-170.
23. MN env gene. J Infect Dis 1995;171:1623-1627.
24. Fries LF, Tartaglia J, Taylor J, Kauffman EK, Meignier B, Paoletti E, and Plotkin S: Human safety and immunogenicity of a canarypox-rabies glycoprotein recombinant vaccine: An alternative poxvirus vector system. Vaccine 1996;14:428-434.
25. Schwartz DH, Mazumdar A, Winston S, and Harkonen S: Utility of various commercially available human immunodeficiency virus (HIV) antibody diagnostic kits for use in conjunction with efficacy trials of HIV-1 vaccines. Clin Diag Lab Immunol 1995;2:268-271.
26. Bartlett JA, Wassermann SS, Hicks CB, Dodge RT, Weinhold KJ, Tacket CO, Ketter N, Wittek AE, Palker TJ, Haynes BF, and the DATRI 010 Study Group: Safety and immunogenicity of an HLA-based HIV envelope polyvalent synthetic peptide immunogen. AIDS 1998;12:1291-1300.
27. Girard M, Meignier B, Barré-Sinoussi F, Kieny MP, Matthews T, Muchmore E, Nara PL, Wei Q, Rimsky L, Weinhold K, and Fultz PN: Vaccine-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1. J Virol 1995;69:6239-6248.
28. Berman PW, Murthy KK, Wrin T, et al.: Protection of MN-rgp120-immunized chimpanzees from heterologous infection with a primary isolate of human immunodeficiency virus type 1. J Infect Dis 1996;173:52-59.
29. El Amad Z, Murthy KK, Heggins K, et al: Resistance of chimpanzees immunized with recombinant gp120 (SF2) to challenge by HIV-1 (SF2). AIDS 1995;9:1313-1322.
30. Zolla-Pazner S, Lubeck M, Robert-Guroff M, et al.: Presence of neutralizing antibodies for primary isolates in immunized chimpanzees correlates with protection in vivo. In: 3rd Conference on Retroviruses and Opportunistic Infections, Washington DC, 1996, p. 131. [Abstract 416]
31. Scarlatti G, Albert J, Rossi P, et al.: Mother-to-child transmission of human immunodeficiency virus type 1: Correlation with neutralizing antibodies against primary isolates. J Infect Dis 1993;168:207-210.
32. Girard M, Barré-Sinoussi F, Tartaglia J, Paoletti E, Van der Ryst E, Nara P, Muchmore E, Mahoney J, Jennings M, and Fultz P: Protection from intravenous and genital HIV-1 challenge in chimpanzees by immunization with an HIV-1 canarypox recombinant. Annual Meeting of the Institute of Human Virology, Baltimore, Maryland. J Acq Immun Defic Synd Hum R 1996. [Abstract 165]
33. Lehner T, Wang Y, Cranage M, Bergmeier LA, Mitchell E, Tao L, Hall G, Dennis M, Cook N, Brookes R, Klavinskis L, Jones I, Doyle C, and Ward R: Protective mucosal immunity elicited by targeted iliac lymph node immunization with a subunit SIV envelope and core vaccine in macaques. Nature Med 1996;2:767-775.
34. Rowland-Jones S, Sutton J, Ariyoshi K, et al.: HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women. Nature Med 1995;1:59-64.
35. Koup RA, Safrit JT, Cao Y, et al.: Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994; 68:4650-4655.
36. Autran B, Hadida F, and Haas G: Evolution and plasticity of CTL responses against HIV. Curr Opin Immunol 1996;8:546-553.
37. Langlade-Demoyen P, Ngo-Giang-Huong N, Ferchal F, and Oskenhendler E: HIV Nef-specific cytotoxic T lymphocytes in non-infected heterosexual contacts of HIV-infected patients. J Clin Invest 1994;93:1293-1297.
38. + cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 1994;68:6103-6110.
39. Bunseyne F and Rivière Y: HIV-specific CD8+ T-cell immune responses and viral replication. AIDS 1993;7:S73-S79.
40. Rivière Y, McChesney MB, Porrot F, et al.: Gag-specific cytotoxic responses to HIV type 1 are associated with a decreased risk of progression to AIDS-related complex of AIDS. AIDS Res Hum Retroviruses 1995;11:903-907.
41. Cheynier R, Langlade-Demoyen P, Marescot MR, et al.: Cytotoxic T lymphocyte responses in the peripheral blood of children born to HIV-1 infected mothers. Eur J Immunol 1992;22:2211-2217.
42. Corey L, Weinhold K, McElrath J, Excler JL, Duliège AM, Clements ML, Belche R, Dolin R, and Graham B: AVEU 022: Safety and immunogenicity of live recombinant canarypox vector containing the envelope, gag, and protease genes of HIV-1 in seronegative adult volunteers. In: XIth International Conference on AIDS, Vancouver, July 1996. [Abstract MoA 282]
43. Ferrari G, Humphrey W, McElrath MJ, Excler JL, Duliege AM, Clements AM, Corey LC, Fast PE, Bolognesi DP, and Weinhold KJ: Clade B-based HIV-1 vaccines elicit cross-clade CTL reactivities in uninfected volunteers. Proc Natl Acad Sci USA 1997; 94:1396-1401.